Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tralokinumab - Leo Pharma

Drug Profile

Tralokinumab - Leo Pharma

Alternative Names: CAT-354

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; LEO Pharma; MedImmune
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 26 Sep 2019 LEO Pharma completes a phase III trial in Atopic dermatitis (Treatment-experienced, Combination therapy) in Belgium, Germany, Canada, Poland, Netherlands and Spain, USA and United Kingdom (SC) (NCT03363854)
  • 14 Aug 2019 LEO Pharma completes the phase III ECZTRA 2 trial in Atopic dermatitis (Monotherapy, Treatment-experienced) in USA, Australia, Canada, Denmark, Italy, South Korea, Poland, Russia, and United Kingdom (NCT03160885)
  • 01 Mar 2019 Efficacy and adverse event data from a phase IIb trial in Atopic dermatitis presented at the 77th Annual Meeting of the American Academy of Dermatology, (AAD-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top